Welcome to our dedicated page for Attovia Therapeutics SEC filings (Ticker: ATTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Attovia Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Attovia Therapeutics's regulatory disclosures and financial reporting.
Attovia Therapeutics, Inc. implemented an Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws on August 6, 2026, in connection with the closing of its initial public offering of common stock, par value $0.0001 per share. The board of directors and stockholders had previously approved these revised governing documents to become effective immediately prior to the offering’s closing, as described in the company’s final prospectus dated August 4, 2026. The company’s common stock trades under the symbol ATTO on the Nasdaq Global Market.
Alamar HoldCo, LLC reported its initial beneficial ownership in Attovia Therapeutics, Inc. as a more than 10% holder on Form 3. The entity holds 3,229,278 shares of Common Stock directly. The remarks state that, in connection with the closing of Attovia’s initial public offering, Alamar HoldCo will cease to be a 10% holder.
Attovia Therapeutics, Inc. director Colin Walsh reported initial indirect holdings of the company’s preferred stock. The filing lists Series B Preferred Stock convertible into 1,957,140 shares of common stock and Series C Preferred Stock convertible into 478,501 shares of common stock, all held through Goldman Sachs–affiliated investment vehicles. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.
Attovia Therapeutics, Inc. is conducting an initial public offering of 17,000,000 shares of common stock at $17.00 per share, for a gross offering of $289,000,000. Underwriters have a 30-day option to purchase up to 2,550,000 additional shares to cover over-allotments. Net proceeds are estimated at $265.1 million (or $305.4 million with full exercise), after underwriting discounts and estimated expenses.
The company is a clinical-stage biopharmaceutical developer of next‑generation biologics for immune‑mediated diseases, built on its proprietary ATTOBODY platform. Lead candidate ATTO-1310 is in a Phase 1 trial for chronic pruritic diseases; ATTO-2306 (bispecific IL‑13/IL‑31) and ATTO-1091 (trispecific TL1A/IL‑23/integrin α4β7) are in IND‑enabling studies with planned Phase 1 trials in the first half of 2027.
As of March 31, 2026, Attovia held $132.6 million in cash, cash equivalents and marketable securities and reported an accumulated deficit of $129.7 million, reflecting net losses of $39.8 million in 2024 and $60.6 million in 2025. The company qualifies as an emerging growth company and smaller reporting company and expects the IPO proceeds, together with existing cash, to fund operations into 2029.